


Express Mail Label No.: EV 392131467 US

Date of Deposit: October 7, 2004

Attorney Docket No.: 23239-558 A



10-08-04 IFW

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

APPLICANTS : Epstein, et al.
SERIAL NUMBER : 10/829,504 EXAMINER : Not Yet Assigned
FILING DATE : April 21, 2004 ART UNIT : 1632
FOR : STABILIZED APTAMERS TO PLATELET DERIVED GROWTH
FACTOR AND THEIR USE AS ONCOLOGY THERAPEUTICS

Mail Stop Amendment

Commissioner for Patents

P.O. Box 1450

Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT

Pursuant to the duty of disclosure under 37 C.F.R. §§1.56, 1.97 and 1.98, Applicants hereby make of record the documents listed on the attached modified Form PTO-1449, as well as copies of the listed documents.

This Information Disclosure Statement is being filed before the mailing date of a first Office Action based on the merits in the above-identified case. Accordingly, no fee or certification is believed required. By the waiver of 37 CFR 1.98(a)(2)(i) copies of the U.S. Patents A1-A37 are not submitted.

It is respectfully requested that the Examiner consider completely the cited information, along with any other information, in reaching a determination concerning the patentability of the present claims, and sign the enclosed form PTO-1449 to evidence that the cited information has been fully considered by the Patent and Trademark Office during the examination of this application.


By submitting this Information Disclosure Statement, the Applicants make no representation that: (1) a search has been performed, of the extent of any search performed, or that more relevant information does not exist; (2) the information cited in the Statement is, or is considered to be, material to patentability as defined in 37 C.F.R. §1.56(b); and (3) the information cited in the Statement is, or is considered to be, in fact, prior art as defined by 35 U.S.C. §102.

APPLICANTS: Epstein et al.
U.S.S.N.: 10/829,504

Notwithstanding any statements by the Applicants, the Examiner is urged to form his/her own conclusion regarding the relevance of the cited information. An early and favorable action is hereby requested.

Please charge any fees that may be due, or credit any overpayment of same, to Deposit Account No. 50-0311, Reference No. 23239-558A.

Respectfully submitted,



Ivor R. Elrifi, Reg. No. 39,529
Jennifer A. Karnakis, Reg. No. 53,097
Attorneys for Applicants
c/o MINTZ, LEVIN
One Financial Center
Boston, Massachusetts 02111
Tel: (617) 542-6000
Fax: (617) 542-2241
Customer No. 30623

Date: October 7, 2004

TRA 1965314v1

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

APPLICANTS : Epstein, et al.
SERIAL NUMBER : 10/829,504 EXAMINER : Not Yet Assigned
FILING DATE : April 21, 2004 ART UNIT : 1632
FOR : STABILIZED APTAMERS TO PLATELET DERIVED GROWTH
FACTOR AND THEIR USE AS ONCOLOGY THERAPEUTICS

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

TRANSMITTAL LETTER

Transmitted herewith for filing in the present application are the following documents:


1. Information Disclosure Statement (2 pages), in duplicate;
2. Modified Form 1449/PTO (5 pages), in duplicate;
3. Copies of Cited References: B1-10; C1-103; and
4. Return Postcard.

If the enclosed papers are considered incomplete, the Mail Room and/or the Application Branch is respectfully requested to contact the undersigned at (617) 542-6000, Boston, Massachusetts.

The Commissioner is authorized to charge any fees that may be due, or to credit any overpayment, to the undersigned's account, Deposit Account No. 50-0311 Ref. No. 23239-558A.

A duplicate copy of this transmittal letter is enclosed herewith.

Respectfully submitted,



For R. Elrifi, Reg. No. 39,529
Jennifer A. Karnakis, Reg. No. 53,097
Attorneys for Applicants
c/o MINTZ, LEVIN
One Financial Center
Boston, Massachusetts 02111
Tel: (617) 542-6000
Fax: (617) 542-2241
Customer No. 30623

Date: October 7, 2004

Express Mail No.: EV 392157521 US
Date of Deposit: October 8, 2004

Page 1 of 5
Attorney Docket No.: 23239-558 A CIP

Please type a plus sign (+) in this box



Modified Form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)	Application Number	10/829,504
	Filing Date	April 21, 2004
	First Named Inventor	Epstein
	Group Art Unit	1632
	Examiner Name	Not Yet Assigned
	Attorney Docket Number	23239-558A

U.S. PATENT DOCUMENTS							
Exam Initials	Cite No.	U.S. Patent Document No.	Issue Date	Name of Patentee(s) or Applicant(s)	Class	Sub Class	Filing Date If Appropriate
	*A1	3,710,795	01/16/73	Higuchi et al.	128	260	
	*A2	5,262,564	11/16/93	Kun et al.	562	430	
	*A3	5,270,163	12/14/93	Gold et al.	435	6	
	*A4	5,475,096	12/12/95	Gold et al.	536	23.1	
	*A5	5,496,938	03/05/96	Gold et al.	536	22.1	
	*A6	5,567,588	10/22/96	Gold et al.	435	6	
	*A7	5,580,737	12/03/96	Polisky et al.	435	6	
	*A8	5,589,332	12/31/96	Shih et al.	435	6	
	*A9	5,637,459	06/10/97	Burke et al.	435	6	
	*A10	5,648,214	07/15/97	Nieuwlandt et al.	435	6	
	*A11	5,660,985	08/26/97	Pieken et al.	435	6	
	*A12	5,668,264	09/16/97	Janjic et al.	536	23.1	
	*A13	5,672,695	09/30/97	Eckstein et al.	536	24.5	
	*A14	5,674,685	10/07/97	Janjic et al.	435	6	
	*A15	5,674,980	10/07/97	Frankel et al.	530	350	
	*A16	5,683,867	11/04/97	Biesecker et al.	435	6	
	*A17	5,698,687	12/16/97	Eckstein et al.	536	25.3	
	*A18	5,705,337	01/06/98	Gold et al.	435	6	
	*A19	5,707,796	01/13/98	Gold et al.	435	6	
	*A20	5,763,177	06/09/98	Gold et al.	435	6	
	*A21	5,804,604	09/08/98	Frankel et al.	530	324	
	*A22	5,817,635	10/06/98	Eckstein et al.	514	44	
	*A23	5,834,186	11/10/98	George et al.	435	6	
	*A24	5,859,228	01/12/99	Janjic et al.	536	24.3	
	*A25	5,958,691	09/28/99	Pieken et al.	435	6	
	*A26	6,011,020	01/04/00	Gold et al.	514	44	
	*A27	6,051,698	04/18/00	Janjic et al.	536	24.31	
	*A28	6,207,646 B1	03/27/01	Krieg et al.	514	44	
	*A29	6,207,816 B1	03/27/01	Gold et al.	536	24.1	
	*A30	6,214,806 B1	04/10/01	Krieg et al.	514	44	
	*A31	6,229,002 B1	05/08/01	Janjic et al.	536	23.1	
	*A32	6,239,116 B1	05/29/01	Krieg et al.	514	44	
	*A33	6,426,434 B1	07/30/02	Yoshida et al.	564	71	
	*A34	6,429,199 B1	08/06/02	Krieg et al.	514	44	

U.S. PATENT DOCUMENTS							
Exam Initials	Cite No.	U.S. Patent Document No.	Issue Date	Name of Patentee(s) or Applicant(s)	Class	Sub Class	Filing Date If Appropriate
	*A35	6,498,148 B1	12/24/02	Raz	514	44	
	*A36	6,514,948 B1	02/04/03	Raz et al.	514	44	
	*A37	6,653,292 B1	11/25/03	Krieg et al.	514	44	

FOREIGN PATENT DOCUMENTS							
Exam Initials	Cite No.	Foreign Patent Document Office	Number	Name of Patentee(s) or Applicant(s)	Date of Publication	Translation Yes	No
	*B1	WO	91/19813	The Univ. of Colorado Foundation, Inc.	12/26/91		
	*B2	WO	92/07065	Maxplanck-Gesellschaft Zur Förderung Der Wissenschaften	04/30/92		
	*B3	WO	98/08974	Intelligene Ltd.	03/05/98		
	*B4	WO	98/18480	Nexstar Pharmaceuticals, Inc.	05/07/98		
	*B5	WO	98/27104	Yale University	06/25/98		
	*B6	WO	99/31276	Nexstar Pharmaceuticals, Inc.	06/24/99		
	*B7	WO	00/70329	Brandeis University	11/23/00		
	*B8	WO	01/66721 A2	Ribozyme Pharmaceuticals, Inc.	09/13/01		
	*B9	WO	02/22882 A2	Archemix Corporation	03/21/02		
	*B10	WO	03/014375 A2	Archemix Corporation	02/20/03		

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS		
Exam Initials	Cite No.	Name of Author, Title (when appropriate), Publication, Volume, Page(s), Date, Etc.
	*C1	Agrawal et al. <i>Ciba Found. Symp.</i> , 209:60-75 (1997)
	*C2	Akhtar et al. <i>Trends Pharmacol. Sci.</i> , 18:12-18 (1997)
	*C3	Antopolsky et al. <i>Bioconjug. Chem.</i> , 10(4):598-606 (1999)
	*C4	Astriab-Fisher et al. <i>Biochem. Pharmacol.</i> , 60(1):83-90 (2000)
	*C5	Bell et al. <i>In Vitro Anim. Cell. Dev. Biol.</i> , 35(9):533-542 (1999)
	*C6	Breaker R.R. <i>Curr. Opin. Biotech.</i> , 7:442-448 (1996)
	*C7	Breaker R.R. <i>Chem. Rev.</i> , 97:371-390 (1997)
	*C8	Breaker R.R. <i>Curr. Opin. Chem. Biol.</i> , 1:26-31 (1997)
	*C9	Breaker R.R. <i>Nat. Biotech.</i> , 15:427-431 (1997)
	*C10	Breaker R.R. Intracellular Ribozyme Applications in Principles and Protocols, pgs. 1-19; Horizon Scientific Press, Wymondham UK, Rossi and Couture, eds., (1999)
	*C11	Breaker R.R. <i>Curr. Opin. Biotech.</i> , 13:31-39 (2002)
	*C12	Carmi et al. <i>Chem. & Biol.</i> , 3:1039-1046 (1996)
	*C13	Carrasquillo et al. <i>Invest. Ophthalmol. Vis. Sci.</i> , 44(1):290-299 (2003)
	*C14	Chen et al. <i>Proc. Natl. Acad. Sci. USA</i> , 100(16):9226-9231 (2003)
	*C15	Cotten et al. <i>Nucl. Acids Res.</i> , 19(10):2629-2635 (1991)
	*C16	Crooke S.T. <i>Adv. Pharmacol.</i> , 40:1-49 (1997)
	*C17	Daniels et al. <i>Anal. Biochem.</i> , 305(2):214-226 (2002)
	*C18	De Rijk et al. <i>Nucl. Acids Res.</i> , 25(22):4679-4684 (1997)
	*C19	Ellington et al. <i>Nature</i> , 346(6287):818-822 (1990)
	*C20	Froehler et al. <i>Nucl. Acids Res.</i> , 14(13):5399-5407 (1986)

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS		
Exam Initials	Cite No.	Name of Author, Title (when appropriate), Publication, Volume, Page(s), Date, Etc.
	*C21	Froehler et al. <i>Tet. Lett.</i> , 27(46):5575-5578 (1986)
	*C22	Gold L. <i>Nat. Biotech.</i> , 20: 671-672 (2002)
	*C23	Golub et al. <i>Cell</i> , 77(2):307-316 (1994)
	*C24	Green et al. <i>Chem. Biol.</i> , 2:683-695 (1995)
	*C25	Greenwald et al. <i>J. Org. Chem.</i> , 60:331-336 (1995)
	*C26	Griffin et al. <i>Gene</i> , 137(1):25-31 (1993)
	*C27	Grindel et al. <i>Antisense Nucl. Acid Drug Dev.</i> , 8(1):43-52 (1998)
	*C28	Hamaguchi et al. <i>Anal. Biochem.</i> , 294:126-131 (2001)
	*C29	Harris et al. <i>Nat. Rev. Drug Discov.</i> , 2(3):214-221 (2003)
	*C30	Hartig et al. <i>Nat. Biotech.</i> , 20:717-722 (2002)
	*C31	Heinreich et al. <i>Science</i> , 299(5607):708-710 (2003)
	*C32	Hirose et al. <i>Tet. Lett.</i> , 28:2449-2452 (1978)
	*C33	Hobbs et al. <i>Biochem.</i> , 12(25):5138-5145 (1973)
	*C34	Jaeger et al. <i>Proc. Natl. Acad. Sci. USA</i> , 86:7706-7710 (1989)
	*C35	Jain et al. <i>Cancer Res.</i> , 47(12):3039-3051 (1987)
	*C36	Jain et al. <i>Adv. Drug Deliv.</i> , 26:71-90 (1997)
	*C37	Jellinek et al. <i>Biochem.</i> , 34(36):11363-11372 (1995)
	*C38	Jenison et al. <i>Antisense Nucl. Acid Drug Dev.</i> , 8(4):265-279 (1998)
	*C39	Jenne et al. <i>Nat. Biotech.</i> , 19:56-61 (2001)
	*C40	Khati et al. <i>J. Virol.</i> , 77(23):12692-12698 (2003)
	*C41	Koizumi et al. <i>Nucl. Acids Symp. Ser.</i> , 42:275-276 (1999)
	*C42	Koizumi et al. <i>Nat. Struct. Biol.</i> , 6(11):1062-1071 (1999)
	*C43	Kraus et al. <i>J. Immunol.</i> , 160:5209-5212 (1998)
	*C44	Krieg A.M. <i>Annu. Rev. Immunol.</i> , 20:709-760 (2002)
	*C45	Lebedeva et al. <i>Eur. J. Pharm. Biopharm.</i> , 50(1):101-119 (2000)
	*C46	Li et al. <i>Curr. Opin. Struct. Biol.</i> , 9:315-323 (1999)
	*C47	Li et al. <i>Proc. Natl. Acad. Sci. USA</i> , 96:2746-2751 (1999)
	*C48	Lin et al. <i>Nucl. Acids Res.</i> , 22(24):5529-5234 (1994)
	*C49	Magnusson et al., <i>Blood</i> , 98(8):2518-2525 (2001)
	*C50	Manoharan M. <i>Antisense Nucl. Acid Drug Dev.</i> , 12(2):103-128 (2002)
	*C51	Marshall et al., <i>Nat. Struct. Biol.</i> , 6(11):992-994 (1999)
	*C52	Mathews et al. <i>J. Mol. Biol.</i> , 288(5):911-940 (1999)
	*C53	Monteith et al. <i>Toxicol. Pathol.</i> , 27(1):8-13 (1999)
	*C54	O'Brien et al. <i>Genes Chromosomes & Cancer</i> , 23(2):187-193 (1998)
	*C55	Ostman et al. <i>Adv. Cancer Res.</i> , 80:1-38 (2001)
	*C56	Padilla et al. <i>Nucl. Acids Res.</i> , 30(24):e138 (2002)
	*C57	Pagratitis et al. <i>Nat. Biotechnol.</i> , 15(1):68-73 (1997)
	*C58	Peng et al. <i>Antisense Nucl. Acid Drug Dev.</i> , 11(1):15-27 (2001)
	*C59	Pieken et al. <i>Science</i> , 253:314-317 (1991)

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS		
Exam Initials	Cite No.	Name of Author, Title (when appropriate), Publication, Volume, Page(s), Date, Etc.
	*C60	Pietersz et al. <i>Vaccine</i> , 19(11-12):1397-1405 (2001)
	*C61	Pietras et al. <i>Cancer Res.</i> , 61:2929-2934 (2001)
	*C62	Pietras et al. <i>Cancer Res.</i> , 62:5476-5484 (2002)
	*C63	Pietras et al. <i>Cancer Cell</i> , 3:439-443 (2003)
	*C64	Potyrailo et al. <i>Anal. Chem.</i> , 70:3419-3425 (1998)
	*C65	Reyderman et al. <i>Pharm. Res.</i> , 15(6):904-910 (1998)
	*C66	Richardson et al. <i>Biochem. Pharmacol.</i> , 59(9):1045-1052 (2000)
	*C67	Richardson et al. <i>Chem. Res. Toxicol.</i> , 15(7):922-926 (2002)
	*C68	Robertson et al. <i>Nucl. Acids Res.</i> , 28(8):1751-1759 (2000)
	*C69	Robertson et al. <i>Nat. Biotech.</i> , 17:62-66 (1999)
	*C70	Robertson et al. <i>Nat. Biotech.</i> , 19:650-655 (2001)
	*C71	Rothbard et al. <i>Nat. Med.</i> , 6(11):1253-1257 (2000)
	*C72	Rothbard J. <i>J. Med. Chem.</i> , 45(17):3612-3618 (2002)
	*C73	Ruckman et al. <i>J. Biol. Chem.</i> , 273(32):20556-20567 (1998)
	*C74	Sassanfar et al. <i>Nature</i> , 364:550-553 (1993)
	*C75	Seetharaman et al. <i>Nat. Biotech.</i> , 19:336-341 (2001)
	*C76	Seiwert et al. <i>Chem. & Biol.</i> , 7:833-843 (2000)
	*C77	Shimizui et al. <i>Cancer Res.</i> , 59:3719-3723 (1999)
	*C78	Simon et al. <i>Nat. Genet.</i> , 15:95-98 (1997)
	*C79	Smidt et al. <i>Nucl. Acids Res.</i> , 19(17):4695-4700 (1991)
	*C80	Smith et al. <i>Cell</i> , 89(5):669-672 (1997)
	*C81	Sood et al. <i>Nucl. Acids Res.</i> , 4(8):2757-2765 (1977)
	*C82	Soukup et al. <i>Proc. Natl. Acad. Sci. USA</i> , 96:3584-3589 (1999)
	*C83	Soukup et al. <i>RNA</i> , 5:1308-1325 (1999)
	*C84	Soukup et al. <i>Structure</i> , 7(7):783-791 (1999)
	*C85	Soukup et al. <i>Tren. Biotech.</i> , 17:469-476 (1999)
	*C86	Soukup et al. in <i>Ribozyme Biochem. Biotech.</i> , Eaton Publishing, Chapter 8, pgs. 149-170, Krupp & Gaur, eds. (2000)
	*C87	Soukup et al. <i>RNA</i> , 7:524-536 (2001)
	*C88	Soukup et al. <i>J. Mol. Biol.</i> , 298:623-632 (2000)
	*C89	Sproat et al. <i>Nucl. Acids Res.</i> , 19(4):733-738 (1991)
	*C90	Srinivasan et al. <i>J. Clin. Lab. Anal.</i> , 9(2):129-137 (1995)
	*C91	Tang et al. <i>Chem. & Biol.</i> , 4:453-459 (1997)
	*C92	Tang et al. <i>Nucl. Acids Res.</i> , 26(18):4214-4221 (1998)
	*C93	Tang et al. <i>RNA</i> , 3:914-925 (1997)
	*C94	Tavitian et al. <i>Nat. Med.</i> , 4(4):467-471 (1998)
	*C95	Tucker et al. <i>J. Chromatography B</i> , 732:203-212 (1999)
	*C96	Tuerk et al. <i>Science</i> , 249(4968):505-510 (1990)
	*C97	Uhlmann et al. <i>Methods Enzymol.</i> , 313:268-284 (2000)
	*C98	Vaish et al. <i>Biochem.</i> , 42(29):8842-8851 (2003)

Date of Deposit: October 8, 2004

Attorney Docket No.: 23239-558 A CIP

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS		
Exam Initials	Cite No.	Name of Author, Title (when appropriate), Publication, Volume, Page(s), Date, Etc.
	*C99	Vives et al. <i>J. Biol. Chem.</i> , 272(25):16010-16017 (1997)
	*C100	Watson et al. <i>Antisense Nucl. Acid Drug Dev.</i> , 10(2):63-75 (2000)
	*C101	Wlotzka et al. <i>Proc. Natl. Acad. Sci. USA</i> , 99(13):8898-8902 (2002)
	*C102	Zubin et al. <i>FEBS Lett.</i> , 456(1):59-62 (1999)
	*C103	Zuker M. <i>Science</i> , 244:48-52 (1989)

* a copy of this reference is not provided as it was previously cited by or submitted to the office in a prior application, Serial No. 10/829,504, filed April 21, 2004 , and relied upon for an earlier filing date under 35 U.S.C. §120 (continuation, continuation-in-part, and divisional applications).

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

TRA 1965293v1